MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
1.860
+0.080
+4.49%
After Hours: 1.910 +0.05 +2.69% 19:59 09/04 EDT
OPEN
1.770
PREV CLOSE
1.780
HIGH
1.950
LOW
1.770
VOLUME
183.11K
TURNOVER
--
52 WEEK HIGH
39.92
52 WEEK LOW
1.640
MARKET CAP
8.24M
P/E (TTM)
-0.1827
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at SKYE last week (0824-0828)?
Weekly Report · 6d ago
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
Benzinga · 08/26 06:07
Skye Bioscience Establishes New Equity Financing Arrangements
TipRanks · 08/24 21:10
Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M
Benzinga · 08/24 20:06
Weekly Report: what happened at SKYE last week (0817-0821)?
Weekly Report · 08/24 09:14
Upcoming Stock Splits This Week (August 24 to August 28) – Stay Invested
TipRanks · 08/23 18:55
Skye Bioscience Inc trading halted, news pending
TipRanks · 08/21 23:50
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.